Der Autor untersucht, welche Rolle der Prüfungsbericht des gesetzlichen Abschlussprüfers ( 321 HGB) einer börsennotierten Aktiengesellschaft für die Corporate Governance spielt.Prof. Markus Müller, MD is Head of the Department of Clinical Pharmacology at the Medical University of Vienna in Austria. He is specialized in Internal Medicine and Clinical Pharmacology and is an international expert in clinical research. He has published over 80 articles on the use and methodology of microdialysis in clinical drug development.